CHENGDU, China, Nov. 18, 2024 — In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as “C Ray”), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding $100 million. This round was co-led by Shenzhen Capital Group Co., Ltd.’s Manufacturing Transformation and Upgrading New Materials Fund (referred to as “SCGC”) and TaiLong Capital, with participation from several renowned institutions and industry players including GL Ventures, 3SBio (01530.HK), Guanghua Wutong, and a well-known industrial investment institution. WinX Capital acted as the exclusive financial advisor for this transaction.

Amidst a backdrop of global economic downturn and increasingly cautious investment trends in the pharmaceutical sector, this milestone achievement further highlights C Ray’s comprehensive strength and development potential in the research, development, production, and clinical application of radiopharmaceuticals.

The main purpose of this round of financing is to further improve the company’s core technology platforms, such as targeted ligand discovery, upgrade the high-throughput screening capabilities for innovative RDC drugs, accelerate the clinical development process of multiple internationally leading R&D pipelines, especially alpha-emitting RDC drugs, and bring more effective treatment options to patients worldwide.

Radiopharmaceuticals are a specialized class of drugs that incorporate radioactive isotopes into specific molecules. These drugs leverage the distinct energy-level rays emitted by different isotopes to either visualize or destroy tumors, thereby integrating diagnosis and therapy. As modern medicine’s demand for precise diagnostics and treatments continues to grow, radiopharmaceuticals have demonstrated significant potential across various fields, including oncology, cardiovascular diseases, and neurological disorders. In 2023, Novartis successfully launched two radioligand therapy drugs, achieving substantial commercial success. Meanwhile, Lilly acquired nuclear medicine company Point for $1.4 billion, and BMS invested $4.1 billion in acquiring RayzeBio, further underscoring the market appeal and promising future of the radiopharmaceutical sector.

C Ray Therapeutics, established in 2021 and headquartered in Chengdu Medical City, is incubated by internationally renowned investment institutions 6 Dimensions Capital. Since its establishment, C Ray has been dedicated to the field of radiopharmaceuticals, aiming for world-class standards. Within just over three years, the company has achieved a series of landmark accomplishments:

• Construction of a nearly 30,000 square meter R&D and production base for radiopharmaceuticals.
• Obtaining the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise.
• Establishing a leading platform with advanced global equipment, cutting-edge technology innovation, and comprehensive functional support in the field of radiopharmaceuticals.

C Ray Therapeutics has established notable advantages in the radiopharmaceutical industry:

• Upstream and Downstream Industrial Chain Layout
  C Ray has secured stable supplies of isotopes and logistics channels for products, enriching resources both upstream and downstream. This ensures the efficient, stable, and comprehensive operation of the supply chain. The company has assembled a multidisciplinary technical team from around the world, continuously building core capabilities in radiochemistry, molecular imaging, radiation dosimetry, and translational medicine. The team has extensive experience with labeling small molecules, peptides, and antibodies using isotopes such as 68Ga, 64Cu, 18F, 89Zr, 177Lu, and 225Ac, covering all stages from pilot studies, intermediate-scale trials, process scaling, non-clinical research, clinical research, to commercial production.
• Advanced R&D and Production Facilities
  The R&D platform can meet the full range of drug development needs, from process development, quality research, and quality inspection to efficacy, pharmacokinetics, and safety evaluations. It has obtained permits for handling over 30 types of medical isotopes and constructed 13 cGMP-standard radiopharmaceutical production workshops compliant with FDA, NMPA, and EMA regulations. These workshops are equipped with fully automated, intelligent, and digital radiopharmaceutical production lines featuring proprietary intellectual property.
• One-stop Customized Services
  Utilizing its top-notch R&D and production facilities, C Ray offers one-stop customized services to partners. These include:
  – Providing CRO services and companion diagnostic development for conventional drugs using molecular imaging.
  – Offering validation services for the druggability of new targets in innovative drug development.
  – Delivering end-to-end CRDMO services for radiopharmaceuticals, from early discovery and PCC verification through IND filing, clinical supply, and commercial production, ensuring high-quality and efficient service throughout the entire process.

Statement from C Ray Therapeutics’ Board of Directors / Management Team:
We extend our heartfelt gratitude to the investors who have provided strong support in this round of financing, as well as to our existing shareholders for their consistent trust. C Ray Therapeutics has now entered a critical phase of rapid development. With the successful launch of our Class A production base, the smooth progress of IIT/clinical trials, overseas business development, and CRDMO services, we are confident that, with the trust and support of our shareholders, C Ray Therapeutics will accelerate the development of innovative radiopharmaceuticals, technologies, and service platforms that maximize benefits for patients. Our goal is to become a leading innovative radiopharmaceutical enterprise not only in China but also globally.

Statement from Shenzhen Capital Group Co., Ltd. (SCGC):
High-end drug carriers have become one of the key technologies in the development of global biomedical technology in recent years. In the field of precision diagnosis and treatment of tumors, the new generation of Radionuclide Drug Conjugates (RDCs) utilize targeted high-end drug carrier materials to conjugate radioactive medical isotope materials, accurately being delivered to the patient’s non-metastatic or metastatic tumor tissue for tumor diagnosis and treatment. We are optimistic about C Ray Therapeutics ‘s innovative capabilities and market prospects, and we also look forward to the company achieving greater breakthroughs in the field of healthcare.

Statement from TaiLong Capital:
In recent years, innovative radiopharmaceuticals have seen rapid development, with continuous breakthroughs in foundational, clinical research, and translational applications. The Chinese radiopharmaceutical industry is steadily advancing and improving, Tailong Capital has also made multiple strategic deployments in investments within this field. We are honored to partner with a company like C Ray Therapeutics, which possesses a spirit of innovation and comprehensive strength. In the future, we look forward to deepening our cooperation with C Ray in areas such as radiopharmaceuticals development and clinical trials, jointly driving the innovation and development of this field.

Statement from GL Ventures:
C Ray Therapeutics boasts unique advantages in the field of radiopharmaceutical R&D, including the ability to integrate and streamline the nuclear industry supply chain. The company has rapidly established a comprehensive industrial system for R&D, production, and supply chain management, thanks to its experienced and efficient execution team. The radioactive biomedicine industry has broad prospects. We believe that under the leadership of the founding team, C Ray Therapeutics will continue to innovate in radiopharmaceutical technology and build a service platform, thereby benefiting a wide range of patients and creating value.

Statement from 3SBio:
In recent years, with the evolving of the nuclear medicine research in China, radiopharmaceuticals have gradually shown a broad development prospect and become a highly hot investment area. Joining the investment in C Ray Therapeutics is in line with 3Sbio’s strategy to explore promising collaboration projects. As a local biopharmaceutical company, we look forward to promoting the R&D of innovative radioactive drugs through this collaboration, helping physicians and patients in China benefit from these brand new therapies.

Statement from Guanghua Wutong:
Since 2021, Wenjiang District, Chengdu City has leveraged the advantages of Sichuan Province as a major nuclear industry province to take a forward-looking approach in the field of radiopharmaceuticals, aiming to create a national-level hub for the radiopharmaceutical industry. C Ray Therapeutics has become one of the benchmark enterprises in Wenjiang’s radiopharmaceutical field. We look forward to the company continuing to delve deeply into Wenjiang, and becoming a world-class platform for research and development, manufacturing, and commercialization in the radiopharmaceutical industry at an early date. This will help to promote the academic development of radiopharmaceuticals and make a greater contribution to the biopharmaceutical industry.

Statement from WinX Capital:
Deeply honored to have served as the exclusive financial advisor for C Ray and to have successfully brought this significant financing round to a close. We are grateful for the trust and recognition from C Ray’s board of directors and management. Innovative radiopharmaceuticals represent one of the fields with the highest potential for blockbuster drugs and significant barriers to entry. C Ray Therapeutics has demonstrated clear advantages in integrating the industry chain. We believe that this round of financing will inject strong momentum into the company’s development, propelling its strategic layout on a global scale.

About Shenzhen Capital Group Co., Ltd. (SCGC)
Established in 1999 with capital contributions from the Shenzhen municipal government and social capital, Shenzhen Capital Group Co., Ltd. (SCGC) is committed to discovering and nurturing great enterprises. SCGC aims to be a discoverer and cultivator of innovative value, and for now has grown into a comprehensive investment group centered on venture capital. SCGC manages a total fund size of more than 480 billion yuan. The SCGC Manufacturing Industry Transformation and Upgrading New Materials Fund is a specific investment vehicle for the National Manufacturing Industry Transformation and Upgrading Fund, focusing primarily on investments in the field of new materials.

About Tailong Capital
Tailong Capital, established in 2021, is a professional equity investment management institution focusing on the fields of biomedicine, medical devices, and healthcare. The scale of the TaiKun Fund managed by Tailong Capital is 20 billion yuan. Tailong Capital has a professional and experienced investment team, focusing on biomedicine, innovative medical devices, CXO services and related innovative fields, as well as outstanding biopharmaceutical industry funds. The company is committed to building a value investment platform for the biopharmaceutical industry that is loyal to science and transcends market cycles.

About GL Ventures
GL Ventures is one of the most active venture capital platforms in China, dedicated to uncovering and creating value in innovative companies, especially in key areas such as new technologies, new energy, new materials, and new consumption. We are committed to providing systematic DVC (Deep Value Creation) services to support the long-term development of early-stage innovative enterprises.

About 3SBio
3SBio is a leading biopharmaceutical company that integrates R&D, production, and sales, dedicated to enhancing patient survival quality and contributing to human health through high-quality medicines. The company holds over 100 national invention patents and offers more than 40 products, covering nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology. 3SBio operates four R&D centers, including the National Engineering Research Center for Antibody Drugs and dual platforms for biopharmaceuticals and chemical drugs, with 28 products under development, 25 of which are national new drugs. The company has five GMP-compliant production bases. Moving forward, 3SBio will continue to uphold the philosophy of “cherishing life, caring for survival, and creating living,” aiming to become a globally leading Chinese biopharmaceutical company.

About Guanghua Wutong
Guanghua Wutong is a wholly-owned subsidiary of Chengdu Guanghua Open Source Capital Management Co., Ltd., the state-owned capital operation platform of Wenjiang District, Chengdu. Adhering to the corporate philosophy of “dedication, professionalism, and sincerity,” Guanghua Wutong focuses on meticulous and efficient investments, striving to build a fund ecosystem and investment service network that deeply roots in the region and radiates nationwide. The company has initiated 13 market-oriented investment funds with a managed capital scale of nearly 10 billion yuan, focusing on key industries such as healthcare, big data, and AI. It has gathered rich industrial resources in biomedicine, advanced medical care, health, big data, and smart manufacturing. The Wenjiang District Industrial Investment Guidance Fund has been selected as one of the “Top 30 Best Government Guidance Funds (District Level)” in China for 2020.

About WinX Capital
WinX Capital is a leading investment bank in the healthcare sector in China, with headquarters in Beijing and Shanghai. The company covers over 3,000 active investment institutions and industry groups. WinX Capital has received numerous accolades, including the “Top Financial Advisor in Healthcare 2022 and 2023” by First Voice, the “Best Financial Advisor in Healthcare 2021-2022” by Qiming Card & NewVoice Innovation Service, and the “Annual Top Financial Advisor in Healthcare 2022-2024” by Artery Network.

SOURCE C Ray Therapeutics

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

BEVERLY, Mass., Nov. 18, 2024 — Quanta Dialysis Technologies, a leader in transforming kidney care through its award-winning Quanta™ Dialysis System, has successfully closed its oversubscribed Series E Preferred Stock financing round, raising more than $60 million of additional capital.

Led by Novo Holdings, Glenview Capital and b2venture, with broad participation by existing shareholders, this latest funding round underscores strong investor confidence in Quanta’s market potential to revolutionize the treatment of kidney disease across a variety of settings.

With the newly secured capital, Quanta will expand its commercial presence in the US and continue to invest in cutting-edge innovation within the sector.

“Our commitment to delivering innovative solutions for acute care has never been stronger,” said Alejandro Galindo, Quanta’s Chief Executive Officer. “This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position.”

“Quanta’s compelling product-market fit within the $1.5 billion acute care segment is demonstrated by its ability to win contracts over well-established legacy CRRT and IHD competitors,” said Robert Ghenchev, Managing Partner of Growth Investments at Novo Holdings. “The recent FDA clearance for the home setting is transformational for patients and significantly expands Quanta’s addressable market into the chronic and sub-acute segments.”

“The team at Quanta continues to deliver on their plan to offer the market a next generation dialysis system that provides exceptional quality care to patients, is easy to use and can provide substantial savings to providers,” adds Lloyd Mandell, Managing Director of Glenview Capital. “We are confident this funding will allow more patients to have access to the Quanta Dialysis System, while allowing the company to achieve their goals of reaching more customers and driving down the cost of their products.”

This milestone marks a significant step towards revolutionizing kidney care and improving patient outcomes. Furthermore, as Quanta advances its growth strategy this latest capital injection will ensure both customers and industry partners can continue to rely on the company’s robust financial foundations.

Notes for editors:

About Quanta Dialysis Technologies

Quanta Dialysis Technologies is committed to making high-quality and cost-effective dialysis accessible to every patient, in every setting, with its Quanta Dialysis System. The Royal Academy of Engineering announced Quanta Dialysis Technologies as the recipient of the 2022 MacRobert Award (the UK’s longest running and most prestigious award for UK engineering innovation), joining the ranks of Rolls-Royce, Arup and Raspberry Pi.

To learn more about Quanta and its products, visit www.quantadt.com.

About the Quanta Dialysis System

As a compact device with performance comparable to larger traditional machines, the Quanta Dialysis System provides the clinical versatility needed to deliver kidney replacement therapy across multiple care settings. With an intuitive user interface and only once-weekly hot rinse requirement, the device is designed to be operated by a broad range of users to bring dialysis directly to patients.

In 2022, Quanta received clearance for the first and only FDA-cleared device able to perform intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED), and CRRT (CVVHD and SCUF) without any need for bags. In 2024, Quanta received FDA-clearance for home hemodialysis (HHD), offering a high dialysate flow (500 mL/min) system.

The SC+ Hemodialysis System is now known as the Quanta Dialysis System.

Photo: https://mma.prnewswire.com/media/2559276/Quanta_Dialysis_System.jpg
Logo:  https://mma.prnewswire.com/media/2548121/5030106/Quanta_Dialysis_Technologies_Logo.jpg

SOURCE Quanta Dialysis Technologies

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

New report finds startup success highest in Colorado, Utah, and Michigan, with strong economies and business-friendly conditions

HAUPPAUGE, N.Y., Nov. 15, 2024 — Location, location, location. It’s not just true of real estate. If you’re interested in starting a business, you might maximize your chances of success if you decide to launch in Colorado. In its inaugural “Best States to Start a Business” report, National Business Capital crowned Colorado the top state for startups, followed by Utah and Michigan. These states combine booming economies, strong access to capital, and manageable taxes – all factors that favor a new venture.

Researchers at the national lending platform for business owners analyzed factors which helped new businesses flourish. Colorado and Utah’s balanced blend of opportunity, growth and support give them a clear edge, while tax-friendly Texas and Florida and high-capital states like California offer unique advantages for aspiring business owners.

The full study is available HERE:

Key Findings

• Top States Lead in Growth and Support – Colorado and Utah dominate with supportive, growth-oriented business environments, while Texas and Florida attract with low taxes, and California offers deep funding resources.
• New England Remains Tough for Startups – High costs and limited support challenge new businesses in New England. Massachusetts is the only state in the region to break the top 10.
• High First-Year Survival in Mid-Atlantic, Long-Term Success in the North – Pennsylvania, New Jersey, and New York report high first-year survival rates. States like Minnesota and Massachusetts excel at five-year survival.
• Stark Survival Rate Drop in Key States – Missouri, New Jersey, and Kentucky have sharp declines from first to fifth-year survival, with Missouri showing a 30% drop.
• Mountain West and Southeast See Highest New Business Applications – Wyoming, Delaware, Colorado, and Utah lead in new business applications, while New England and the northern heartland lagged.

“With a good business plan, hard work and a little luck, you can succeed anywhere,” said Joe Camberato, CEO, National Business Capital. “If, for instance, my cousin wanted to open a business and she could move anywhere in the country, I would urge her to read this study carefully.”

THE BEST U.S. STATES TO START A BUSINESS IN 2025

1.Colorado (score out of 100): 71

2.Utah (score: 68.1) – tie

2.Michigan (score: 68.1) – tie

4.Texas (score: 66.1)

5.Florida (score: 64.3)

6.California (score: 64.2)

7.Minnesota (score: 63)

8.Indiana (score: 62.7)

9.Massachusetts (score: 62.1)

10.Ohio (score: 61.6)

THE WORST U.S. STATES TO START A BUSINESS IN 2025:

41. New Hampshire (Score: 45.0 out of 100)
42. Wisconsin (43.1)
43. Maine (41.3)
44. New Mexico (40.7)
45. Arkansas (40.4)
46. Oregon (40.2)
47. Vermont (40)
48. West Virginia (39.3)
49. Rhode Island (35.7)
50. Kansas (29.4)

METRICS

Year One Survival Rates (12%)
Year Five Survival Rates (18%)
GDP Per Capita (8%)
LLC Filing Costs (4%)
LLC Annual Costs (6%)
Top Corporate Tax Rate (7.5%)
Business Applications Per Capita (13%)
Venture Capital Per Capita (8%)
SBA Loan Approvals Per 100,000 Residents (11%)
Gross Receipts Tax (5%)
Personal Income Tax (7.5%)

About NationalBusinessCapital:

NationalBusinessCapital helps entrepreneurs secure quick and fair financing to save time and cultivate sustainable growth.

The company’s stress-free online platform is designed for simplicity and speed, helping business owners go from application to approval in a matter of hours. From SBA loans to lines of credit, equipment financing, and more, business owners can access all the different financing programs available to them in one place.

For more information on this list and this topic, please contact Sarah Johnson, [email protected].

CONTACT

Sarah Johnson

[email protected]

SOURCE National Business Capital

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

BURLINGAME, Calif., Nov. 15, 2024 — In 2022, AidQuest transformed the home care industry with a seemingly simple solution: a 12-line JavaScript code. This innovation has propelled nearly 1,000 agencies toward unprecedented growth, turning their websites from mere information displays into dynamic platforms that actively engage visitors and convert them into leads.

The home care sector spends millions on SEO and paid advertising to drive traffic to their websites. However, the industry faces a significant challenge: high bounce rates. On average, visitors spend less than 20 seconds on a site before leaving, often overwhelmed by the plethora of options provided by search engines like Google. This constant back-and-forth not only inflates advertising costs but also benefits search engines at the expense of agency owners.

AidQuest’s human live chat platform is changing the game. By introducing real-time, human-led conversations, the platform ensures that visitors are immediately engaged, reducing bounce rates and increasing conversion opportunities. Results speak volumes: one national brand garnered over 7,000 client leads and 14,000 caregiver applicants, boosting their revenue by $4 million in just 12 months. Similarly, a local agency reported 110 new client leads and a $300k revenue increase, alongside 120 caregiver applicants, significantly enhancing their staffing quality.

“In the year since we started working with AidQuest the number of leads we have received from our websites has more than doubled. AidQuest human chat has become an integral part of our digital strategy,” says Peter Ross, CEO & Co-Founder of Senior Helpers (www.seniorhelpers.com).

Kamran Nasser, Founder of AidQuest, emphasizes the urgency of engagement: “You have only about 20 seconds to capture your visitor’s attention. Without human interaction, 90% leave without taking any action.” Greg McCarthy, Chief Growth Officer, adds, “Our HIPAA-compliant, one-on-one conversations filter through the noise, identifying genuine inquiries and converting them into qualified leads tailored to agency-specific criteria.”

The home care industry is poised for significant growth, driven by the aging baby boomer generation — a demographic that is expected to represent 20% of the U.S. population by 2030. As this population ages, the demand for in-home care services is rapidly increasing, creating both challenges and opportunities in this sector. AidQuest’s innovative solutions are timely, helping agencies meet this surging demand by optimizing their digital platforms to engage effectively with families seeking reliable and compassionate care for their loved ones.

About AidQuest®:
Founded by former home care agency owners, AidQuest® offers a unique, human-powered 24/7 Live-Chat platform (www.aidquest.com) by merging top-tier technology with personal human touch. AidQuest’s solutions empower home care agencies to provide more efficient, faster and better care to more people.

Contact:
Kamran Nasser
6504778125
[email protected]

SOURCE AidQuest

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

SEATTLE, Nov. 14, 2024 — TestSprite, pioneering AI-powered autonomous software testing, today announced the close of a $1.5 million pre-seed round, bringing the total funding amount raised to $1.7 million. Investors included Techstars, Jinqiu Capital, MiraclePlus, Hat-trick Capital, EdgeCase Capital Partners, and angel investor Rafael Barroso. Additional investment came from the founding team. Funds will accelerate product development, expand the team, and scale operations to meet growing demand.

Funding comes on the heels of TestSprite introducing an early access beta program for its forthcoming end-to-end QA tool, which fully automates testing across back-end and front-end systems. TestSprite’s autonomous testing tool aims to free individual developers and resource-constrained teams from traditional software QA and AI co-pilot testing tools that still require time-consuming steps or manual intervention.

The global automation testing market is expanding rapidly, with Polaris Research projecting the AI coding tools market to reach $27 billion by 2032. And, as AI-generated code becomes increasingly prevalent, developers face growing challenges in testing and validating complex code they didn’t write. Current AI co-pilot tools still produce bugs while leaving critical gaps in testing and debugging. TestSprite’s tool addresses this directly, delivering comprehensive validation without manual inspection, accelerating development cycles 10x faster.

“Automated testing is becoming more crucial as AI-assisted software development rapidly becomes the de-facto way of building software in a market that is pushing for faster, more efficient software delivery from software engineers. We believe the Testsprite team and product is poised to become the leader in this new market shift,” said Andres Barreto, Managing Director at Techstars.

Yunhao Jiao, co-founder and CEO of TestSprite stated, “With this funding, we’re excited to ready our autonomous testing tool. As AI-generated code becomes more complex, our vision is to let AI test AI, allowing developers to focus on innovation while maintaining software quality. We’re grateful for our investors’ support and look forward to scaling to meet market demands.”

Sign Up for Early Access
The company is offering a free community version for developers to test drive its fully autonomous software testing tool. Due to demand, priority access will be given to developers willing to share feedback and help refine TestSprite’s testing tool.

About TestSprite
Based in Seattle, Washington, privately-held TestSprite is pioneering the industry’s first AI-powered software testing agent, especially for those using GenAI coding. Its mission is to simplify software testing for resource-limited dev teams worldwide. TestSprite accelerates end-to-end software dev cycles by eliminating manual testing, delivering speed improvements of up to ten times. The company’s innovative tool leverages advanced AI and machine learning to deliver comprehensive test coverage with minimal developer input, significantly improving confidence in software releases.

Press Contact:
Carmen Hughes
Ignite X
[email protected] 
650.576.6444

SOURCE TestSprite

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

Backed by True Ventures, Team-GPT enables teams to leverage AI in a collaborative workspace and propel internal use of AI in data-secure way.

SOFIA, Bulgaria, Nov. 14, 2024 — Bulgarian startup Team-GPT has amassed a user base of 45,000+ for its AI-driven collaborative workspace for the enterprise. Salesforce, MRO, and Johns Hopkins University are among the large-scale organizations using Team-GPT. The startup recently secured a $4.5 million seed round led by Silicon Valley venture capital firm True Ventures with participation from Pact and angel investors, including ex-OpenAI employees.

Many companies are unsure how to integrate generative artificial intelligence (GenAI) effectively in their workflows. The challenges are manifold, from identifying relevant AI use cases and collaborating on them, through managing AI models from major players like OpenAI, Anthropic, and Meta, to making sure the data remains safe through compliance standards like SOC-2 and ISO 27001.

Team-GPT allows users within enterprises to interact with any AI model, organize prompts, and discover actionable AI use cases. This facilitates an easy integration of AI into business processes, empowering companies to decrease hiring needs and dramatically enhance productivity.

“For decades, communicating with AI was a complicated task reserved for scientists. GPT changed the game and allowed anyone to take advantage of AI, by simply chatting,” said Iliya Valchanov, co-founder and CEO of Team-GPT. “While chat is simple to understand, it’s rather limiting. When working with files, editing text, or  automating workflows, instead of chat, we need novel AI-first experiences, the likes of which we offer in Team-GPT. Moreover, to truly adopt AI, enterprises will require a great deal of education and change management – something we’ve dealt with as a team when cloud and data science platforms started to emerge.”

Valchanov is a renowned AI instructor, having educated 1,400,000+ working professionals globally. He founded the company alongside co-founders Ilko Kacharov, Yavor Belakov, Katya Vaptsarova, and Maria Valchanova. Together, they are on a mission to help enterprises uncover practical AI applications for their unique needs.

“Knowledge workers are using generative AI to improve their work,” said Mike Montano, investor at True Ventures. “Pair that with enterprise concerns about data protection and it makes for a real challenge in adopting tools across teams. Team-GPT brings all of that silo-ed work into a workspace that will become a new home for AI-driven collaboration. We’re excited to see this come to life, get to invest and support the team’s journey.”

In addition to large enterprise organizations like Salesforce, the impact of Team-GPT has been widely recognized by leaders across myriad industries.

“Team-GPT supports our entire value chain—from strategy development and conceptualization to content creation. We’ve seen 60% productivity increase anywhere that content generation is required” shared Michael Frank, CEO of Die Crew.

“We’ve accelerated our deal closure time by 35% using Team-GPT. It’s like having a team of expert analysts working 24/7 to accelerate our operations.” shared Jeko Kolev, CEO of Nextoria.

In an era where GenAI technologies like ChatGPT and Claude are set to revolutionize industries, the potential for superhuman productivity is unprecedented.

About Team-GPT

Team-GPT is an enterprise AI software where teams of nontechnical users can collaborate. The platform includes: a shared chat interface, an agent workflow builder, file management systems, and a word processor with embedded AI. Learn how Team-GPT’s AI toolbox can help your team work better together and discover the use cases that can be solved by AI at team-gpt.com.

Photo: https://mma.prnewswire.com/media/2551857/Team_GPT_Founders.jpg
Logo:  https://mma.prnewswire.com/media/2551859/Team_GPT_Logo.jpg

For PR inquiries:

Margarita Arsova
[email protected]
+359887558765

SOURCE Team-GPT

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

With Series A funding, Vaulted, already delivering CDR at the fastest rate across the industry, will develop additional injection well sites to deliver more CDR at an increasing pace. 

HOUSTON, Nov. 14, 2024 — Vaulted Deep (“Vaulted”), a biomass carbon removal and storage (BiCRS) company specializing in durable carbon dioxide removal (CDR), announced today that it has raised $32.3 million in Series A funding. The round was led by new investor Prelude Ventures and returning investors with super pro rata participation including from Lowercarbon Capital, Earthshot Ventures, and WovenEarth Ventures. Additional new investors include Fall Line Capital and Rethink Impact.

“This funding comes on the heels of Vaulted’s first full year of successful operations and will allow the company to expand carbon dioxide removal capacity, including adding new deep injection well sites in the coming years. Vaulted Deep’s rapid progress from seed funding to Series A, from concept to high-volume delivery, demonstrates the immense potential of its approach,” said Matt Eggers, Managing Partner at Prelude Ventures. “We believe Vaulted’s technology can lead the way to durable carbon removal at a meaningful scale, and we are excited to support their mission to deliver real, lasting climate solutions.”

As a spinoff from an established waste disposal company, Vaulted launched in late 2023 with existing, permitted well infrastructure and an experienced team. This has allowed the company to deliver CDR quickly and safely using mature, proven injection technology.

Vaulted has already issued more than 7,000 tonnes of CDR, achieving the industry’s fastest and highest rate of deliveries in the first year of operations for durable CDR (source: CDR.fyi). In May 2024, Frontier announced that it had facilitated a $58.3 million offtake agreement with Vaulted Deep to permanently remove 152,480 tonnes of CO₂ between 2024 and 2027. Currently, Vaulted is now generating CDR at a rate of over 1,500 per month. With this additional funding, Vaulted will begin to move forward on its next U.S. facility, Monarch Fields.  

“Rapid scalable deliveries are essential to helping the CDR industry grow in a sustainable and impactful way,” said Julia Reichelstein, Co-Founder and CEO of Vaulted Deep. “By leveraging our legacy assets and expertise, our vision has always been to lead the charge on speed and scale. With this next round of funding, Vaulted will supercharge on both fronts by developing new wells for more CDR removal —and delivering more tonnes, faster, to meet rising industry demand.”

“The magnitude and pace of Vaulted’s durable carbon removal deliveries stem from decades of experience perfecting our technology in industrial waste management,” said Vaulted Co-founder and Executive Chairman Omar Abou Sayed. “Our successful Series A accelerates our ability to open new sites across multiple geographies, including our new facility Monarch Fields, leveraging our proven technology to fill customer demand while delivering benefits beyond carbon removal to our customers and the communities we serve.”

Vaulted’s approach starts with vegetation naturally drawing down CO₂ from the atmosphere via photosynthesis. Much of that ends up as carbon-rich waste in the form of biosolids, manure, food or agricultural waste that is incinerated, landfilled, or spread on land. As that waste burns or decomposes, the once-captured CO₂ is released back into the atmosphere. Vaulted prevents that from happening by turning that waste into a carbon-rich slurry and then injecting it into deep disposal wells for permanent geologic storage. By processing a range of often pathogenic and contaminated organic wastes, Vaulted’s CDR provides substantial co-benefits that include eliminating methane emissions (which Vaulted does not include in its credit accounting), reducing water-borne illnesses, and preventing serious water and agricultural soil pollution. By using natural processes to capture CO₂ via biomass, Vaulted’s technology bypasses costly carbon capture infrastructure, delivering rapid, permanent CDR without compromising scalability.

About Vaulted Deep

Vaulted Deep is a biomass carbon removal and storage (BiCRS) carbon removal company, geologically sequestering organic wastes deep into the subsurface. Vaulted Deep’s mission is to urgently combat climate change by permanently removing carbon from the atmosphere, while avoiding methane and protecting local land, air, and water. Vaulted Deep spun off of Advantek Waste Management Services, and is backed by Prelude Ventures, Lowercarbon Capital, Earthshot Ventures, WovenEarth Ventures, Fall Line Capital, Rethink Impact and others. To learn more, go to www.vaulteddeep.com.

About Prelude Ventures

Prelude Ventures is a climate-focused venture capital firm that invests in and supports early-stage startups with the greatest potential to mitigate climate change. For over a decade, Prelude Ventures has sought out purpose-driven founders and provided the capital and expertise needed to build the next generation of category-defining businesses that will reshape our global economy for the greater good of people and the planet. Located in San Francisco, Prelude Ventures has approximately $2 billion under management.

SOURCE Vaulted Deep

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

Essential guide for entrepreneurs and investors to navigate the unique world of robotics startups will be available online

BOSTON, Nov. 14, 2024 — Cybernetix Ventures, a venture capital firm leading the way for investments into early-stage robotics, automation, and industrial AI, today announced the release of The Robotics Startup Playbook, an online guide for navigating the unique challenges of building and scaling robotics ventures. The Playbook leverages the Cybernetix team’s combined 50 years of past and ongoing experience and a forward-looking vision to create a guide for founders, investors and ecosystem leaders in robotics. With insights into critical topics—like choosing vertical markets and use cases, product scoping and development to balance hardware with scalable software, and models to maximize revenue—it allows founders, investors and leaders to make informed decisions in a rapidly accelerating industry that is poised for explosive growth.

The Robotics Startup Playbook currently contains six chapters that will be released throughout the coming months. It is for entrepreneurs, investors and ecosystem leaders who see the powerful mega-trends of robotics, industrial AI, and automation, and who want to learn the key success factors and common challenges of building, scaling and investing in these areas.

“Whether you’re an investor looking to understand the unique dynamics of robotics as a unique investment class, or an entrepreneur aiming to build and scale a disruptive robotics company, this playbook is for you,” said Fady Saad, Founder & Managing Partner, Cybernetix Ventures. “It’s designed to provide actionable insights, highlight common pitfalls, and guide industry leaders in shaping the future of robotics.”

Founded in 2021, Cybernetix Ventures supports the most promising robotics founders and startups by partnering with robotics clusters worldwide to elevate these companies to a global stage, connecting them with a diverse ecosystem of potential customers, later-stage investors, financial institutions, and acquirers.

“There are a lot of misconceptions about robotics. It’s no longer such a capital-intensive endeavor and the paths to revenues and scaling can be much faster than in the past. But, the funding profile can be different as compared to SaaS investing. It’s quite typical to see an additional seed round or additional Series A round to get to revenue acceleration and P&L that a growth stage investor wants to see,” commented Mark Martin, Co-founder & General Partner, Cybernetix Ventures. “The reward with good robotics startups is very sticky businesses with high value deployed hardware that can be combined with additional revenue streams from data, value-added software, services, and consumables. So, while robotics requires a shift in mindset for investors, those who understand the long-term value stand to benefit significantly.”

About Cybernetix Ventures

Cybernetix Ventures is a unique venture capital firm leading the way for investments into early-stage robotics, automation, and industrial AI startups. Headquartered in Boston, Cybernetix connects its portfolio to national and global robotics ecosystems, bringing unparalleled expertise to companies poised to make major impacts in large, essential sectors – manufacturing, logistics, construction, healthcare, climate and agriculture. The firm’s portfolio includes companies across North America and Europe. Cybernetix is committed to delivering on three pillars of value: exceptional support for founders, phenomenal returns to LPs, and impactful ecosystem leadership for robotics communities. Cybernetix is led by Fady Saad and Mark Martin, who have decades of robotics technologies, operations and investing experience. The firm pioneered Robotics Invest, an annual summit where top founders, investors, and business leaders in robotics come together to build the next wave of robotics unicorns.

SOURCE Cybernetix Ventures

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

Miami-based and Latina-founded Influur sees record growth in 2024 with 83% spike in active influencers on its platform and 200% growth in brand spend on influencer-powered campaigns

MIAMI, Nov. 14, 2024 — Today, Influur, the leading professional networking platform for influencers founded by visionary Latinas – Alessandra Angelini, Valeria Angelini, Paula Coleman, and Fefi Oliveira – announced the successful closing of its $10 million Series A, led by Point72 Ventures and HTwenty Capital. The funding highlights Influur’s hypergrowth, including an 83% increase in its verified influencer base and a 200% rise in brand spend across the US and Latin America. The company now has over 30K active influencers and 5,000 brands on its platform across 11 countries.

Influur has built the most comprehensive platform for the creator economy that goes beyond traditional influencer marketing. It is a vibrant global community that empowers influencers to monetize their talent, expand their reach, and grow their businesses. It streamlines connections between brands and influencers, allowing them to build meaningful relationships and impactful campaigns together. And unlike platforms that rely on scraping data, Influur ensures all its influencers are verified and registered, making it a trusted platform for both the creator community and brands.

“Influur is a connected community where influencers ‘find home’—gaining access to brand opportunities and resources to thrive,” said Alessandra Angelini, co-founder and CEO of Influur. “This funding will help us enhance our platform, enabling influencers to grow their businesses and connect with brands more effectively.”

As part of today’s announcement, Influur is introducing an industry-first AI feature to help brands plan the right influencer campaigns and predict its impact; a new Premium Subscription for influencers with advanced analytics, AI-powered media kit creation, and access to exclusive campaigns and events; as well as a suite of fintech tools designed to manage earnings, payouts, and financial insights – positioning the platform to be the future bank for influencers.

Miami-based Influur has quickly become a leader in the influencer space, driven by its adoption by top influencers like Lele Pons and Twan Kuyper; global brand customers including Meta, Warner Music Group, Paramount, Netflix, UberEats, Hard Rock Cafe, MasterCard, and TikTok; and investment from key figures from the music and entertainment industries, including Colombian actress Sofia Vergara, singer and actress Thalía, entertainment executive Luis Balaguer, and Latin World Entertainment. Additional investors include Magma Partners, Daedalus, IGNIA, Redwood, Vamos Ventures, Amplifica Capital, and Daniel Gutenberg.

“We are drawn to bold ideas and commitment to innovation, and Influur embodies both,” said Ishan Sinha, Partner at Point72 Ventures. “These four entrepreneurs have impressed us with their vision to empower creators by placing their values and resources at the forefront. We are confident in the team’s ability to execute and drive meaningful change in this rapidly evolving industry, and we look forward to being part of their journey.”

Leveraging AI for Unprecedented Foresight and Efficiency
Influur is developing an AI-powered recommendation system that will be integrated directly into Pulse, its desktop application. It will be engineered to recommend the strategy of a campaign as well as predict the investment and impact of influencer marketing campaigns within moments, offering unprecedented foresight and budget efficiency. It will be the only recommendation system of its kind available in the market, positioning Influur at the forefront of innovation in influencer marketing and brand campaigns.

“Our AI recommendation engine is a game-changer,” added Valeria Angelini, CPO of Influur. “By harnessing AI, we’re enabling brands and influencers to make smarter, data-driven decisions faster than ever before.”

Influur Premium Supercharges Influencer Careers
Influur Premium is a new subscription that provides unique professional tools designed to supercharge their careers. Included in this subscription is access to:

• Automated Media Kit Creation: Generate a professional media kit in seconds, complete with live social media analytics and a portfolio of past collaborations. This time-saving tool helps influencers put their best work forward every time a brand asks for a portfolio and eliminates the manual creation process.
• Access to Exclusive Premium Campaigns: Premium members unlock campaigns available only to them, catered by top-tiered brands. It’s a win:win – brands have access to top-tiered professional creators while influencers get access to experiences and networking opportunities developed specifically for them.
• Exclusive Experiences: Exclusive experiences provide influencers with invaluable exposure to other industry professionals, in a fun environment with esteemed partners based in Miami, including top yoga studios, premier padel clubs, and renowned restaurants.
• Advanced Analytics Tools: Influencers can now leverage daily insights into social media performance with their sophisticated analytics suite, enabling them to stay ahead of trends and optimize their strategies.

Influencer and Brand Quotes

• Lele Pons, Influencer & Actress:
  • “I’ve worked with brands around the world and no one has paid me as fast as Influur. This app stands out from any other influencer platform I’ve used,” shared Lele Pons. “The community is exceptional, and the app’s features, especially the Wallet payment system, make getting paid quick and easy. It’s inspiring to work with a company founded by four incredible Latinas. With Influur Premium, I’ve enjoyed exclusive opportunities like Formula 1 and Copa America.”
• Luis Baez, Advocacy Manager, Flor de Caña:
  • “At Rum Flor de Caña, we’re thrilled to partner with Influur to craft innovative influencer marketing campaigns that resonate with cultural moments, making a meaningful impact and connecting with our communities in fresh, exciting ways.”

For more information about Influur, or to sign up as an influencer or brand, visit www.influur.com.

About Influur
Influur is the leading platform and community empowering the creator industry by helping influencers monetize their talents and build successful careers. The company was founded by four visionary Latinas, each from an entrepreneurial background with experience across media, marketing, fashion, content creation, and technology. Since 2021, 30K influencers have joined the Influur community, using the platform and its tools to connect with 5,000+ brands, build new partnerships, seamlessly manage their business and payouts, and expand their reach and influence.

Maria Larrazabal
[email protected]

SOURCE Influur

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In